MARKET

IKT

IKT

Inhibikase Therapeutics Inc
NASDAQ
1.990
+0.050
+2.58%
After Hours: 1.920 -0.07 -3.50% 18:58 07/02 EDT
OPEN
1.970
PREV CLOSE
1.940
HIGH
2.040
LOW
1.950
VOLUME
679.00K
TURNOVER
--
52 WEEK HIGH
2.260
52 WEEK LOW
1.330
MARKET CAP
262.74M
P/E (TTM)
-4.5145
1D
5D
1M
3M
1Y
5Y
1D
Inhibikase grants stock options for 981,243 shares to seven new hires under inducement plan at $2.03 per share
PUBT · 2d ago
Inhibikase Shareholders Approve Governance and Compensation Changes
TipRanks · 5d ago
Inhibikase Therapeutics holds annual shareholder meeting
PUBT · 5d ago
Weekly Report: what happened at IKT last week (0622-0626)?
Weekly Report · 5d ago
Weekly Report: what happened at IKT last week (0615-0619)?
Weekly Report · 06/22 09:12
Weekly Report: what happened at IKT last week (0608-0612)?
Weekly Report · 06/15 09:11
Inhibikase Therapeutics Price Target Announced at $5.00/Share by Oppenheimer
Dow Jones · 06/10 18:12
Oppenheimer Initiates Coverage On Inhibikase Therapeutics with Outperform Rating, Announces Price Target of $5
Benzinga · 06/10 18:02
More
About IKT
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).

Webull offers Inhibikase Therapeutics Inc stock information, including NASDAQ: IKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IKT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IKT stock methods without spending real money on the virtual paper trading platform.